Celgene Corporation (CELG) : Edinburgh Partners Ltd reduced its stake in Celgene Corporation by 13.91% during the most recent quarter end. The investment management company now holds a total of 490,847 shares of Celgene Corporation which is valued at $51,180,617 after selling 79,280 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Oct 11, 2016.Celgene Corporation makes up approximately 9.58% of Edinburgh Partners Ltd’s portfolio.
Other Hedge Funds, Including , Oregon Public Employees Retirement Fund reduced its stake in CELG by selling 18,864 shares or 19.07% in the most recent quarter. The Hedge Fund company now holds 80,059 shares of CELG which is valued at $8,347,752. Celgene Corporation makes up approx 0.18% of Oregon Public Employees Retirement Fund’s portfolio.First Mercantile Trust Co reduced its stake in CELG by selling 9,583 shares or 15.68% in the most recent quarter. The Hedge Fund company now holds 51,520 shares of CELG which is valued at $5,361,686. Celgene Corporation makes up approx 0.72% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in CELG in the latest quarter, The investment management firm added 192,259 additional shares and now holds a total of 488,072 shares of Celgene Corporation which is valued at $51,389,101. Celgene Corporation makes up approx 0.21% of Bnp Paribas Arbitrage Sa’s portfolio.Bath Savings Trust Co boosted its stake in CELG in the latest quarter, The investment management firm added 2,033 additional shares and now holds a total of 87,439 shares of Celgene Corporation which is valued at $9,206,452. Celgene Corporation makes up approx 2.90% of Bath Savings Trust Co’s portfolio.
Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.